201 related articles for article (PubMed ID: 25750072)
61. Prevalence of HIV Associated Neurocognitive Disorder using Modified Mini Mental State Examination and its Correlation with CD4 Counts and Anti-retroviral Therapy.
Kumar S; Himanshu D; Tandon R; Atam V; Sawlani KK; Verma SK
J Assoc Physicians India; 2019 Apr; 67(4):47-51. PubMed ID: 31299839
[TBL] [Abstract][Full Text] [Related]
62. What's in a name? AIDS dementia complex, HIV-associated dementia, HIV-associated neurocognitive disorder or HIV encephalopathy.
Singh D
Afr J Psychiatry (Johannesbg); 2012 May; 15(3):172-5. PubMed ID: 22722724
[TBL] [Abstract][Full Text] [Related]
63. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India.
Riedel D; Ghate M; Nene M; Paranjape R; Mehendale S; Bollinger R; Sacktor N; McArthur J; Nath A
J Neurovirol; 2006 Feb; 12(1):34-8. PubMed ID: 16595372
[TBL] [Abstract][Full Text] [Related]
64. Interrelations among patterns of change in neurocognitive, CT brain imaging and CD4 measures associated with anti-retroviral therapy in children with symptomatic HIV infection.
Brouwers P; DeCarli C; Tudor-Williams G; Civitello L; Moss H; Pizzo P
Adv Neuroimmunol; 1994; 4(3):223-31. PubMed ID: 7874390
[TBL] [Abstract][Full Text] [Related]
65. Sex differences in cognitive function among people with HIV-1 clade C infection in Northern India.
Sharma A; Mohanty M; Salan T; Aggarwal D; Mandell L; Jones DL; Arheart K; Sharma A; Vyas S; Singh P; Govind V; Kumar M
J Neurovirol; 2023 Oct; 29(5):614-625. PubMed ID: 37698788
[TBL] [Abstract][Full Text] [Related]
66. Education effects on the International HIV Dementia Scale.
Waldrop-Valverde D; Nehra R; Sharma S; Malik A; Jones D; Kumar AM; Ownby RL; Wanchu A; Weiss S; Prabhakar S; Kumar M
J Neurovirol; 2010 Jul; 16(4):264-7. PubMed ID: 20578972
[TBL] [Abstract][Full Text] [Related]
67. Cognitive changes in asymptomatic drug-naïve human immunodeficiency virus type 1 clade C infection.
Gopukumar K; Rao SL; Satishchandra P; Dasgupta J; Ellis RJ; Subbakrishna DK; Mariamma P; Kamat A; Desai A; Ravi V; Rao BS; Satish KS; Kumar M
J Neurovirol; 2008 Nov; 14(6):480-5. PubMed ID: 19021075
[TBL] [Abstract][Full Text] [Related]
68. Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders.
Tyor W; Fritz-French C; Nath A
J Neurovirol; 2013 Dec; 19(6):515-22. PubMed ID: 24129908
[TBL] [Abstract][Full Text] [Related]
69. Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders.
Gendelman HE; Gelbard HA
Curr Opin HIV AIDS; 2014 Nov; 9(6):585-90. PubMed ID: 25226025
[TBL] [Abstract][Full Text] [Related]
70. Plasma anti-CD4 IgG is associated with brain abnormalities in people with HIV on antiretroviral therapy.
Bowler S; Mitchell BI; Kallianpur KJ; Chow D; Jiang W; Shikuma CM; Ndhlovu LC
J Neurovirol; 2021 Apr; 27(2):334-339. PubMed ID: 33710596
[TBL] [Abstract][Full Text] [Related]
71. Neurocognitive Phenotyping of HIV in the Era of Antiretroviral Therapy.
Paul R
Curr HIV/AIDS Rep; 2019 Jun; 16(3):230-235. PubMed ID: 31168712
[TBL] [Abstract][Full Text] [Related]
72. Neurocognitive impact of antiretroviral treatment: thinking long-term.
McPhail ME; Robertson KR
Curr HIV/AIDS Rep; 2011 Dec; 8(4):249-56. PubMed ID: 21837444
[TBL] [Abstract][Full Text] [Related]
73. Peptide T for cognitive impairment.
Smart T
GMHC Treat Issues; 1995 Sep; 9(9):15. PubMed ID: 11362907
[TBL] [Abstract][Full Text] [Related]
74. HIV Clade-C Infection and Cognitive Impairment, Fatigue, Depression, and Quality of Life in Early-Stage Infection in Northern Indians.
Cook R; Jones DL; Nehra R; Kumar AM; Prabhakar S; Waldrop-Valverde D; Sharma S; Kumar M
J Int Assoc Provid AIDS Care; 2016 Jul; 15(4):332-7. PubMed ID: 23722088
[TBL] [Abstract][Full Text] [Related]
75. Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy.
Oshinaike OO; Akinbami AA; Ojo OO; Ojini IF; Okubadejo UN; Danesi AM
AIDS Res Treat; 2012; 2012():581531. PubMed ID: 23050130
[TBL] [Abstract][Full Text] [Related]
76. Peptide T.
GMHC Treat Issues; 1995 Dec; 9(12):8. PubMed ID: 11363001
[TBL] [Abstract][Full Text] [Related]
77. Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans.
Fourie CM; Schutte AE; Smith W; Kruger A; van Rooyen JM
Atherosclerosis; 2015 May; 240(1):154-60. PubMed ID: 25795556
[TBL] [Abstract][Full Text] [Related]
78. Mortality hazard and survival after tuberculosis treatment.
Miller TL; Wilson FA; Pang JW; Beavers S; Hoger S; Sharnprapai S; Pagaoa M; Katz DJ; Weis SE
Am J Public Health; 2015 May; 105(5):930-7. PubMed ID: 25790407
[TBL] [Abstract][Full Text] [Related]
79. CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy.
Peeling RW; Sollis KA; Glover S; Crowe SM; Landay AL; Cheng B; Barnett D; Denny TN; Spira TJ; Stevens WS; Crowley S; Essajee S; Vitoria M; Ford N
PLoS One; 2015; 10(3):e0115019. PubMed ID: 25790185
[TBL] [Abstract][Full Text] [Related]
80. Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study.
Thuppal SV; Wanke CA; Noubary F; Cohen JT; Mwamburi M; Ooriapdickal AC; Muliyil J; Kang G; Varghese GM; Rupali P; Karthik R; Sathasivam R; Clarance P; Pulimood SA; Peter D; George L
Trans R Soc Trop Med Hyg; 2015 Jun; 109(6):379-85. PubMed ID: 25778734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
